|  |
| --- |
|  **Supplemental table 1 Baseline and procedural characteristics and laboratory data in patients with critical limb ischemia** |
|  |  **NLR < 5**  |  **NLR ≥ 5** |  **P** |
|  |  **N = 104** |  **N = 91** |  |
|  **Age (years)** | **74.2**  | **(12.0)** | **73.7**  | **(11.1)** | **0.755**  |
|  **Male gender** | **55** | **52.9%** | **46** | **50.5%** | **0.745** |
|  **Body mass index (kg/m2)** | **23.5**  | **(3.8)** | **23.4**  | **(4.6)** | **0.916**  |
|  **Heart rate at baseline (beats per minute)** | **84.8**  | **(15.4)** | **92.1**  | **(19.6)** | **0.004**  |
|  **Systolic BP at baseline (mm Hg)** | **148.0**  | **(31.5)** | **146.6**  | **(31.9)** | **0.745**  |
|  **Diastolic BP at baseline (mm Hg)** | **73.3**  | **(12.8)** | **77.3**  | **(16.0)** | **0.051**  |
|  **Current/past smoker** | **28** | **26.9%** | **18** | **19.8%** | **0.241** |
|  **Alcohol intake** | **30** | **28.8%** | **25** | **27.5%** | **0.874** |
|  **Family history of premature CAD** | **1** | **1.0%** | **1** | **1.5%** | **0.924** |
|  **History of hypertension** | **75** | **72.1%** | **54** | **59.3%** | **0.06** |
|  **History of diabetes mellitus** | **74** | **71.2%** | **60** | **65.9%** | **0.433** |
|  **History of insulin use** | **15** | **14.4%** | **10** | **11.0%** | **0.474** |
|  **History of dyslipidemia** | **17** | **16.3%** | **16** | **17.6%** | **0.818** |
| **Normal kidney function** | **64** | **61.5%** | **59** | **64.8%** | **0.653** |
|  **Chronic kidney disease** | **20** | **19.2%** | **13** | **14.3%** |  |
|  **End-stage renal disease** | **20** | **19.2%** | **19** | **20.9%** |  |
|  **History of CAD** | **40** | **38.5%** | **35** | **38.5%** | **1** |
|  **History of old myocardial infarction** | **7** | **6.7%** | **6** | **6.6%** | **0.969** |
|  **History of atrial fibrillation** | **17** | **16.3%** | **9** | **9.9%** | **0.186** |
|  **History of chronic heart failure** | **23** | **22.2%** | **19** | **20.8%** | **0.943** |
|  **NYHA class I** | **6** | **58.0%** | **4** | **4.4%** | **0.432** |
|  **NYHA class II** | **4** | **3.8%** | **8** | **8.8%** | **0.432** |
|  **NYHA class III** | **9** | **8.7%** | **6** | **6.6%** | **0.432** |
|  **NYHA class IV** | **4** | **3.8%** | **1** | **1.1%** | **0.432** |
|  **History of carotid artery stenosis** | **3** | **2.9%** | **0** | **0.0%** | **0.103** |
|  **History of ischemic stroke** | **20** | **19.2%** | **14** | **15.4%** | **0.48** |
|  **Ongoing Cancer** | **8** | **7.7%** | **4** | **4.4%** | **0.339** |
|  **History of amputation** |  |  |  |  | **0.500** |
|  **Above-knee amputation** | **2** | **1.9%** | **4** | **4.4%** |  |
|  **Below-knee amputation** | **2** | **1.9%** | **1** | **1.1%** |  |
|  **Forefoot amputation** | **2** | **1.9%** | **2** | **2.2%** |  |
|  **Presented with acute ischemic limb** | **8** | **7.7%** | **20** | **22.0%** | **0.005** |
|  **Rutherford classification** |  |  |  |  | **0.009** |
|  **class IV** | **37** | **35.6%** | **16** | **17.6%** |  |
|  **class V** | **63** | **60.6%** | **66** | **72.5%** |  |
| **class VI** | **4** | **3.8%** | **9** | **9.9%** |  |
| **Laboratory data** |  |  |  |  |  |
|  **Total cholesterol (mg/dl)** | **162.9**  | **(46.4)** | **147.9**  | **(47.7)** | **0.033**  |
|  **High-density lipoprotein cholesterol (mg/dl)** | **42.8**  | **(19.7)** | **37.3**  | **(17.0)** | **0.230**  |
|  **Low-density lipoprotein cholesterol (mg/dl)** | **94.2**  | **(36.3)** | **89.9**  | **(38.6)** | **0.637**  |
|  **Triglyceride (mg/dl)** | **153.4**  | **(127.9)** | **135.6**  | **(91.0)** | **0.290**  |
|  **Fasting glucose (mg/dl)** | **178.4**  | **(92.1)** | **181.5**  | **(118.4)** | **0.836**  |
|  **Glycosylated hemoglobin (%)** | **7.4**  | **(1.7)** | **7.6**  | **(2.1)** | **0.626**  |
|  **Creatinine (mg/dl)** | **3.1**  | **(2.7)** | **3.8**  | **(3.8)** | **0.140**  |
|  **Alanine transaminase (IU/L)** | **17.9**  | **(10.2)** | **28.6**  | **(29.1)** | **0.001**  |
|  **Uric acid (mg/dl)** | **5.5**  | **(2.1)** | **6.1**  | **(2.7)** | **0.151**  |
|  **White blood cell count 103 / *u*L** | **7.2**  | **(2.6)** | **12.7**  | **(5.6)** | **<0.001** |
|  **Neutrophil ratio (%)** | **61.5**  | **(11.5)** | **82.0**  | **(6.2)** | **<0.001** |
|  **Lymphocyte ratio (%)** | **23.1**  | **(6.9)** | **8.1**  | **(3.6)** | **<0.001** |
|  **NLR** | **2.9**  | **(1.0)** | **14.2**  | **(12.1)** | **<0.001** |
|  **Medication use at baseline** |  |  |  |  |  |
|  **Aspirin** | **41** | **39.4%** | **26** | **28.6%** | **0.111** |
|  **Cilostazol** | **57** | **54.8%** | **33** | **36.3%** | **0.01** |
|  **Clopidogrel** | **23** | **22.1%** | **30** | **33.0%** | **0.089** |
|  **Pentoxyphylline** | **5** | **4.8%** | **3** | **3.3%** | **0.596** |
|  **ACEI or ARB** | **6** | **5.8%** | **3** | **3.3%** | **0.412** |
|  **Beta-blocker** | **21** | **20.2%** | **14** | **15.4%** | **0.383** |
|  **Calcium channel block** | **20** | **19.2%** | **19** | **20.9%** | **0.774** |
|  **Statin** | **25** | **24.0%** | **12** | **13.2%** | **0.054** |
|  **Urate lowering therapy** | **1** | **1.0%** | **4** | **4.4%** | **0.13** |

**Values were expressed as number and (standard deviation) or number and percentage.**

**CAD = coronary artery disease; NYHA = New York Heart Association; BP = blood pressure; NLR = neutrophil-lymphocyte ratio; ACEI = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor blockers.**